NVP 1102

Drug Profile

NVP 1102

Alternative Names: NVP-1102

Latest Information Update: 03 Aug 2016

Price : $50

At a glance

  • Originator Navipharm
  • Class Muscle relaxants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Spasm

Most Recent Events

  • 31 Mar 2015 Launched for Spasm in South Korea (unspecified route)
  • 30 Nov 2014 Preregistration for Spasm in South Korea (unspecified route)
  • 30 Nov 2014 Phase-III clinical trials in Spasm in South Korea (unspecified route) prior to November 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top